Stephen R Cole

List of Publications by Year
in descending order

216 papers	15,158 citations	41339 49 h-index	19747 117 g-index
219 all docs	219 docs citations	219 times ranked	20455 citing authors

#	Article	IF	Citations
1	Constructing Inverse Probability Weights for Marginal Structural Models. American Journal of Epidemiology, 2008, 168, 656-664.	3.4	1,880
2	Overadjustment Bias and Unnecessary Adjustment in Epidemiologic Studies. Epidemiology, 2009, 20, 488-495.	2.7	1,441
3	Competing Risk Regression Models for Epidemiologic Data. American Journal of Epidemiology, 2009, 170, 244-256.	3.4	984
4	Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet, The, 2009, 373, 1352-1363.	13.7	676
5	Illustrating bias due to conditioning on a collider. International Journal of Epidemiology, 2010, 39, 417-420.	1.9	638
6	Adjusted survival curves with inverse probability weights. Computer Methods and Programs in Biomedicine, 2004, 75, 45-49.	4.7	607
7	Fallibility in estimating direct effects. International Journal of Epidemiology, 2002, 31, 163-165.	1.9	494
8	Generalizing Evidence From Randomized Clinical Trials to Target Populations: The ACTG 320 Trial. American Journal of Epidemiology, 2010, 172, 107-115.	3.4	352
9	The Use of Propensity Scores to Assess the Generalizability of Results from Randomized Trials. Journal of the Royal Statistical Society Series A: Statistics in Society, 2011, 174, 369-386.	1.1	332
10	Selection Bias Due to Loss to Follow Up in Cohort Studies. Epidemiology, 2016, 27, 91-97.	2.7	292
11	The Consistency Statement in Causal Inference. Epidemiology, 2009, 20, 3-5.	2.7	287
12	Invited Commentary: Positivity in Practice. American Journal of Epidemiology, 2010, 171, 674-677.	3.4	268
13	Effect of Highly Active Antiretroviral Therapy on Time to Acquired Immunodeficiency Syndrome or Death using Marginal Structural Models. American Journal of Epidemiology, 2003, 158, 687-694.	3.4	234
14	Empirical Comparison of Publication Bias Tests in Meta-Analysis. Journal of General Internal Medicine, 2018, 33, 1260-1267.	2.6	184
15	Multiple-imputation for measurement-error correction. International Journal of Epidemiology, 2006, 35, 1074-1081.	1.9	183
16	Generalizing Study Results. Epidemiology, 2017, 28, 553-561.	2.7	181
17	Transportability of Trial Results Using Inverse Odds of Sampling Weights. American Journal of Epidemiology, 2017, 186, 1010-1014.	3.4	181
18	Principled Approaches to Missing Data in Epidemiologic Studies. American Journal of Epidemiology, 2018, 187, 568-575.	3.4	169

#	ARTICLE	IF	CITATIONS
19	Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. Aids, 2007, 21, 1739-1745.	2.2	159
20	Splines for Trend Analysis and Continuous Confounder Control. Epidemiology, 2011, 22, 874-875.	2.7	148
21	Structural accelerated failure time models for survival analysis in studies with time-varying treatments. Pharmacoepidemiology and Drug Safety, 2005, 14, 477-491.	1.9	147
22	Multiple Imputation for Incomplete Data in Epidemiologic Studies. American Journal of Epidemiology, 2018, 187, 576-584.	3.4	143
23	Invited Commentary: Causal Diagrams and Measurement Bias. American Journal of Epidemiology, 2009, 170, 959-962.	3.4	139
24	Maximum Likelihood, Profile Likelihood, and Penalized Likelihood: A Primer. American Journal of Epidemiology, 2014, 179, 252-260.	3.4	136
25	An Introduction to G Methods. International Journal of Epidemiology, 2017, 46, dyw323.	1.9	132
26	The role of the câ€statistic in variable selection for propensity score models. Pharmacoepidemiology and Drug Safety, 2011, 20, 317-320.	1.9	128
27	The Parametric g-Formula for Time-to-event Data. Epidemiology, 2014, 25, 889-897.	2.7	127
28	Viremia Copy-Years Predicts Mortality Among Treatment-Naive HIV-Infected Patients Initiating Antiretroviral Therapy. Clinical Infectious Diseases, 2011, 53, 927-935.	5.8	122
29	Marginal Structural Models for Estimating the Effect of Highly Active Antiretroviral Therapy Initiation on CD4 Cell Count. American Journal of Epidemiology, 2005, 162, 471-478.	3.4	106
30	The Effect of Highly Active Antiretroviral Therapy on the Survival of HIV-Infected Children in a Resource-Deprived Setting: A Cohort Study. PLoS Medicine, 2011, 8, e1001044.	8.4	100
31	Estimating the odds ratio when exposure has a limit of detection. International Journal of Epidemiology, 2009, 38, 1674-1680.	1.9	98
32	Target Validity and the Hierarchy of Study Designs. American Journal of Epidemiology, 2019, 188, 438-443.	3.4	95
33	Serum uric acid in relation to endogenous reproductive hormones during the menstrual cycle: findings from the BioCycle study. Human Reproduction, 2013, 28, 1853-1862.	0.9	92
34	Use of a Marginal Structural Model to Determine the Effect of Aspirin on Cardiovascular Mortality in the Physicians' Health Study. American Journal of Epidemiology, 2002, 155, 1045-1053.	3.4	91
35	The parametric gâ€formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death. Statistics in Medicine, 2012, 31, 2000-2009.	1.6	89
36	Accuracy Loss Due to Selection Bias in Cohort Studies with Left Truncation. Paediatric and Perinatal Epidemiology, 2013, 27, 491-502.	1.7	89

#	ARTICLE	IF	CITATIONS
37	Copy-Years Viremia as a Measure of Cumulative Human Immunodeficiency Virus Viral Burden. American Journal of Epidemiology, 2010, 171, 198-205.	3.4	85
38	Limitation of Inverse Probability-of-Censoring Weights in Estimating Survival in the Presence of Strong Selection Bias. American Journal of Epidemiology, 2011, 173, 569-577.	3.4	79
39	Standardized binomial models for risk or prevalence ratios and differences. International Journal of Epidemiology, 2015, 44, 1660-1672.	1.9	77
40	Inverse probability‐of‐censoring weights for the correction of time‐varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death. Statistics in Medicine, 2009, 28, 1725-1738.	1.6	76
41	Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. American Journal of Epidemiology, 2019, 188, 1569-1577.	3.4	75
42	Generalizing Evidence from Randomized Trials Using Inverse Probability of Sampling Weights. Journal of the Royal Statistical Society Series A: Statistics in Society, 2018, 181, 1193-1209.	1.1	69
43	Linear Regression With an Independent Variable Subject to a Detection Limit. Epidemiology, 2010, 21, S17-S24.	2.7	68
44	Risk. American Journal of Epidemiology, 2015, 181, 246-250.	3.4	66
45	Joint effects of alcohol consumption and high-risk sexual behavior on HIV seroconversion among men who have sex with men. Aids, 2013, 27, 815-823.	2.2	61
46	Neighborhood Poverty and Injection Cessation in a Sample of Injection Drug Users. American Journal of Epidemiology, 2010, 171, 391-398.	3.4	60
47	Hospital-Acquired Clostridium difficile Infections. Epidemiology, 2014, 25, 570-575.	2.7	59
48	Worth the Weight: Using Inverse Probability Weighted Cox Models in AIDS Research. AIDS Research and Human Retroviruses, 2014, 30, 1170-1177.	1.1	58
49	Time Scale and Adjusted Survival Curves for Marginal Structural Cox Models. American Journal of Epidemiology, 2010, 171, 691-700.	3.4	54
50	Estimation of the Standardized Risk Difference and Ratio in a Competing Risks Framework: Application to Injection Drug Use and Progression to AIDS After Initiation of Antiretroviral Therapy. American Journal of Epidemiology, 2015, 181, 238-245.	3.4	54
51	Statistical methods for multivariate meta-analysis of diagnostic tests: An overview and tutorial. Statistical Methods in Medical Research, 2016, 25, 1596-1619.	1.5	54
52	The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009–11. International Journal of Epidemiology, 2016, 45, 140-150.	1.9	53
53	Analysis of Occupational Asbestos Exposure and Lung Cancer Mortality Using the G Formula. American Journal of Epidemiology, 2013, 177, 989-996.	3.4	49
54	Incidence and Trends in Hypoglycemia Hospitalization in Adults With Type 1 and Type 2 Diabetes in England, 1998–2013: A Retrospective Cohort Study. Diabetes Care, 2017, 40, 1651-1660.	8.6	49

#	ARTICLE	IF	CITATIONS
55	Periodontitis and Non‐alcoholic Fatty Liver Disease, a population‐based cohort investigation in the Study of Health in Pomerania. Journal of Clinical Periodontology, 2017, 44, 1077-1087.	4.9	49
56	Determining the Effect of Highly Active Antiretroviral Therapy on Changes in Human Immunodeficiency Virus Type 1 RNA Viral Load using a Marginal Structural Left-censored Mean Model. American Journal of Epidemiology, 2007, 166, 219-227.	3.4	48
57	Association of Household Opioid Availability and Prescription Opioid Initiation Among Household Members. JAMA Internal Medicine, 2018, 178, 102.	5.1	47
58	Malaria, malnutrition, and birthweight: A meta-analysis using individual participant data. PLoS Medicine, 2017, 14, e1002373.	8.4	46
59	When to Censor?. American Journal of Epidemiology, 2018, 187, 623-632.	3.4	46
60	All your data are always missing: incorporating bias due to measurement error into the potential outcomes framework. International Journal of Epidemiology, 2015, 44, 1452-1459.	1.9	44
61	Sensitivity analysis for an unobserved moderator in RCT-to-target-population generalization of treatment effects. Annals of Applied Statistics, 2017, 11, .	1.1	44
62	The effect of HIV infection on overdose mortality. Aids, 2005, 19, 935-942.	2.2	43
63	Validity of US norms for the Bayley Scales of Infant Development-III in Malawian children. European Journal of Paediatric Neurology, 2014, 18, 223-230.	1.6	43
64	Time-modified Confounding. American Journal of Epidemiology, 2009, 170, 687-694.	3.4	42
65	Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment. Aids, 2010, 24, 1341-1349.	2.2	41
66	Causal Impact: Epidemiological Approaches for a Public Health of Consequence. American Journal of Public Health, 2016, 106, 1011-1012.	2.7	40
67	Enrollment, Retention, and Visit Attendance in the University of North Carolina Center for AIDS Research HIV Clinical Cohort, 2001–2007. AIDS Research and Human Retroviruses, 2010, 26, 875-881.	1.1	39
68	Effects of Antiretroviral Therapy and Depressive Symptoms on All-Cause Mortality Among HIV-Infected Women. American Journal of Epidemiology, 2017, 185, 869-878.	3.4	38
69	Randomized Controlled Trial of an Intervention to Maintain Suppression of HIV Viremia After Prison Release: The imPACT Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 81-90.	2.1	38
70	Assessment and Indirect Adjustment for Confounding by Smoking in Cohort Studies Using Relative Hazards Models. American Journal of Epidemiology, 2014, 180, 933-940.	3.4	37
71	Imputation approaches for potential outcomes in causal inference. International Journal of Epidemiology, 2015, 44, 1731-1737.	1.9	37
72	Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies. Statistics in Medicine, 2004, 23, 3351-3363.	1.6	36

#	ARTICLE	IF	CITATIONS
73	Age at Entry Into Care, Timing of Antiretroviral Therapy Initiation, and 10-Year Mortality Among HIV-Seropositive Adults in the United States. Clinical Infectious Diseases, 2015, 61, 1189-1195.	5.8	36
74	Impact of Health Insurance, ADAP, and Income on HIV Viral Suppression Among US Women in the Women's Interagency HIV Study, 2006â€"2009. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 307-312.	2.1	34
75	Estimating the Effects of Multiple Time-varying Exposures Using Joint Marginal Structural Models. Epidemiology, 2012, 23, 574-582.	2.7	33
76	Causal Inference in Occupational Epidemiology: Accounting for the Healthy Worker Effect by Using Structural Nested Models. American Journal of Epidemiology, 2013, 178, 1681-1686.	3.4	33
77	Association of early HIV viremia with mortality after HIV-associated lymphoma. Aids, 2013, 27, 2365-2373.	2.2	33
78	Ten-year Survival by Race/Ethnicity and Sex Among Treated, HIV-infected Adults in the United States. Clinical Infectious Diseases, 2015, 60, 1700-1707.	5.8	33
79	Inverse probability of treatment-weighted competing risks analysis: an application on long-term risk of urinary adverse events after prostate cancer treatments. BMC Medical Research Methodology, 2017, 17, 93.	3.1	33
80	Breast Cancer Subtypes and Previously Established Genetic Risk Factors: A Bayesian Approach. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 84-97.	2.5	31
81	Effect of Highly Active Antiretroviral Therapy on Multiple AIDS-defining Illnesses among Male HIV Seroconverters. American Journal of Epidemiology, 2006, 163, 310-315.	3.4	30
82	Effect of Highly Active Antiretroviral Therapy on Incident AIDS Using Calendar Period as an Instrumental Variable. American Journal of Epidemiology, 2009, 169, 1124-1132.	3.4	30
83	An information criterion for marginal structural models. Statistics in Medicine, 2013, 32, 1383-1393.	1.6	30
84	Inverse-Probability-Weighted Estimation for Monotone and Nonmonotone Missing Data. American Journal of Epidemiology, 2018, 187, 585-591.	3.4	30
85	Beyond binary retention in HIV care. Aids, 2018, 32, 2217-2225.	2.2	29
86	Sensitivity Analyses for Sparse-Data Problemsâ€"Using Weakly Informative Bayesian Priors. Epidemiology, 2013, 24, 233-239.	2.7	27
87	African American Race and HIV Virological Suppression: Beyond Disparities in Clinic Attendance. American Journal of Epidemiology, 2014, 179, 1484-1492.	3.4	27
88	Estimating the Effect of Cumulative Occupational Asbestos Exposure on Time to Lung Cancer Mortality. Epidemiology, 2014, 25, 246-254.	2.7	27
89	Effect of acyclovir on herpetic ocular recurrence using a structural nested model. Contemporary Clinical Trials, 2005, 26, 300-310.	1.8	26
90	Using Marginal Structural Measurement-Error Models to Estimate the Long-term Effect of Antiretroviral Therapy on Incident AIDS or Death. American Journal of Epidemiology, 2010, 171, 113-122.	3.4	25

#	ARTICLE	IF	CITATIONS
91	Association Between Unprotected Ultraviolet Radiation Exposure and Recurrence of Ocular Herpes Simplex Virus. American Journal of Epidemiology, 2014, 179, 208-215.	3.4	25
92	Introduction to computational causal inference using reproducible Stata, R, and Python code: A tutorial. Statistics in Medicine, 2022, 41, 407-432.	1.6	25
93	Effect of tuberculosis on the survival of HIV-infected men in a country with low tuberculosis incidence. Aids, 2008, 22, 1869-1873.	2.2	24
94	A simulation study of finite-sample properties of marginal structural Cox proportional hazards models. Statistics in Medicine, 2012, 31, 2098-2109.	1.6	24
95	Safety of Dynamic Intravenous Iron Administration Strategies in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 728-737.	4.5	24
96	Incomplete viral suppression and mortality in HIV patients after antiretroviral therapy initiation. Aids, 2017, 31, 1989-1997.	2.2	23
97	Generalizing Randomized Clinical Trial Results: Implementation and Challenges Related to Missing Data in the Target Population. American Journal of Epidemiology, 2018, 187, 817-827.	3.4	23
98	Quantifying bias between reported last menstrual period and ultrasonography estimates of gestational age in Lusaka, Zambia. International Journal of Gynecology and Obstetrics, 2019, 144, 9-15.	2.3	23
99	Pregnancy and Virologic Response to Antiretroviral Therapy in South Africa. PLoS ONE, 2011, 6, e22778.	2.5	23
100	A prospective study of alcohol consumption and HIV acquisition among injection drug users. Aids, 2011, 25, 221-228.	2.2	22
101	A Comparison of Methods to Estimate the Hazard Ratio Under Conditions of Time-varying Confounding and Nonpositivity. Epidemiology, 2011, 22, 718-723.	2.7	21
102	Meta-analysis of randomized trials on the association of prophylactic acyclovir and HIV-1 viral load in individuals coinfected with herpes simplex virus-2. Aids, 2011, 25, 1265-1269.	2.2	21
103	Self-Reported Reproductive Tract Infections and Ultrasound Diagnosed Uterine Fibroids in African-American Women. Journal of Women's Health, 2015, 24, 489-495.	3.3	21
104	Assessing the component associations of the healthy worker survivor bias: occupational asbestos exposure and lung cancer mortality. Annals of Epidemiology, 2013, 23, 334-341.	1.9	20
105	Sensitivity analyses for effect modifiers not observed in the target population when generalizing treatment effects from a randomized controlled trial: Assumptions, models, effect scales, data scenarios, and implementation details. PLoS ONE, 2018, 13, e0208795.	2.5	20
106	Bayesian Posterior Distributions Without Markov Chains. American Journal of Epidemiology, 2012, 175, 368-375.	3.4	19
107	The Role of At-Risk Alcohol/Drug Use and Treatment in Appointment Attendance and Virologic Suppression Among HIV+ African Americans. AIDS Research and Human Retroviruses, 2014, 30, 233-240.	1.1	19
108	US Black Women and Human Immunodeficiency Virus Prevention: Time for New Approaches to Clinical Trials. Clinical Infectious Diseases, 2017, 65, 324-327.	5.8	18

#	Article	IF	Citations
109	Loss to Clinic and Five-Year Mortality among HIV-Infected Antiretroviral Therapy Initiators. PLoS ONE, 2014, 9, e102305.	2.5	18
110	Effect of discontinuing antiretroviral therapy on survival of women initiated on highly active antiretroviral therapy. Aids, 2004, 18, 1579-1584.	2.2	17
111	Ongoing life stressors and suicidal ideation among HIV-infected adults with depression. Journal of Affective Disorders, 2016, 190, 322-328.	4.1	17
112	Primary non‑adherence and the new‑user design. Pharmacoepidemiology and Drug Safety, 2018, 27, 361-364.	1.9	17
113	HbA 1C variability and hypoglycemia hospitalization in adults with type 1 and type 2 diabetes: A nested case-control study. Journal of Diabetes and Its Complications, 2018, 32, 203-209.	2.3	17
114	Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence. Aids, 2014, 28, 979-987.	2.2	16
115	RESOLVING AN APPARENT PARADOX IN DOUBLY ROBUST ESTIMATORS. American Journal of Epidemiology, 2018, 187, 891-892.	3.4	16
116	Virologic suppression and CD4+ cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens. Aids, 2018, 32, 261-266.	2.2	16
117	Comparison of Methods to Generalize Randomized Clinical Trial Results Without Individual-Level Data for the Target Population. American Journal of Epidemiology, 2019, 188, 426-437.	3.4	16
118	Revisiting Overadjustment Bias. Epidemiology, 2021, 32, e22-e23.	2.7	16
119	Determinants of alcohol consumption in HIV-uninfected injection drug users. Drug and Alcohol Dependence, 2010, 111, 173-176.	3.2	15
120	Marginal Structural Models for Case-Cohort Study Designs to Estimate the Association of Antiretroviral Therapy Initiation With Incident AIDS or Death. American Journal of Epidemiology, 2012, 175, 381-390.	3.4	15
121	Exploring racial differences in the obesity gender gap. Annals of Epidemiology, 2015, 25, 420-425.	1.9	15
122	Dietary intake and risk of non-severe hypoglycemia in adolescents with type 1 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 1340-1347.	2.3	15
123	Multiple Imputation to Account for Measurement Error in Marginal Structural Models. Epidemiology, 2015, 26, 645-652.	2.7	14
124	Incident AIDS or Death After Initiation of Human Immunodeficiency Virus Treatment Regimens Including Raltegravir or Efavirenz Among Adults in the United States. Clinical Infectious Diseases, 2017, 64, 1591-1596.	5.8	14
125	Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features. JNCI Cancer Spectrum, 2021, 5, pkaa072.	2.9	14
126	Aspirin in the primary prevention of cardiovascular disease in the Women's Health Study: Effect of noncompliance. European Journal of Epidemiology, 2012, 27, 431-438.	5.7	13

#	Article	IF	Citations
127	Outcomes of pharmacist-assisted management of antiretroviral therapy in patients with HIV infection: A risk-adjusted analysis. American Journal of Health-System Pharmacy, 2015, 72, 1463-1470.	1.0	13
128	Exploring the Subtleties of Inverse Probability Weighting and Marginal Structural Models. Epidemiology, 2018, 29, 352-355.	2.7	13
129	Evaluating the Population Impact on Racial/Ethnic Disparities in HIV in Adulthood of Intervening on Specific Targets: A Conceptual and Methodological Framework. American Journal of Epidemiology, 2018, 187, 316-325.	3.4	13
130	An Illustration of Inverse Probability Weighting to Estimate Policy-Relevant Causal Effects. American Journal of Epidemiology, 2016, 184, 336-344.	3.4	12
131	A hybrid Bayesian hierarchical model combining cohort and case–control studies for meta-analysis of diagnostic tests: Accounting for partial verification bias. Statistical Methods in Medical Research, 2016, 25, 3015-3037.	1.5	12
132	Chlamydia trachomatis Seroprevalence and Ultrasound-Diagnosed Uterine Fibroids in a Large Population of Young African-American Women. American Journal of Epidemiology, 2018, 187, 278-286.	3.4	12
133	Using Bounds to Compare the Strength of Exchangeability Assumptions for Internal and External Validity. American Journal of Epidemiology, 2019, 188, 1355-1360.	3.4	12
134	Effects of time-varying exposures adjusting for time-varying confounders: the case of alcohol consumption and risk of incident human immunodeficiency virus infection. International Journal of Public Health, 2010, 55, 227-228.	2.6	11
135	Stressful and traumatic life events as disruptors to antiretroviral therapy adherence. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 1378-1385.	1.2	11
136	G-computation for policy-relevant effects of interventions on time-to-event outcomes. International Journal of Epidemiology, 2021, 49, 2021-2029.	1.9	11
137	Mortality under plausible interventions on antiretroviral treatment and depression in HIV-infected women: an application of the parametric g-formula. Annals of Epidemiology, 2017, 27, 783-789.e2.	1.9	10
138	Risk factors for delayed antiretroviral therapy initiation among HIV-seropositive patients. PLoS ONE, 2017, 12, e0180843.	2.5	10
139	Nonparametric Bounds for the Risk Function. American Journal of Epidemiology, 2019, 188, 632-636.	3.4	10
140	Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial. BMC Pregnancy and Childbirth, 2019, 19, 81.	2.4	10
141	Controversy and Debate: Questionable utility of the relative risk in clinical research: Paper 2: Is the Odds Ratio "portable"in meta-analysis? Time to consider bivariate generalized linear mixed model. Journal of Clinical Epidemiology, 2022, 142, 280-287.	5.0	10
142	Poverty, Deprivation, and Mortality Risk Among Women With HIV in the United States. Epidemiology, 2021, 32, 877-885.	2.7	10
143	Controversy and Debate : Questionable utility of the relative risk in clinical research: Paper 4 :Odds Ratios are far from "portable"– A call to use realistic models for effect variation in meta-analysis. Journal of Clinical Epidemiology, 2022, 142, 294-304.	5.0	10
144	Five-Year Mortality for Adults Entering Human Immunodeficiency Virus Care Under Universal Early Treatment Compared With the General US Population. Clinical Infectious Diseases, 2022, 75, 867-874.	5.8	10

#	Article	IF	Citations
145	Estimation of cumulative odds ratios. Annals of Epidemiology, 2004, 14, 172-178.	1.9	9
146	Sample size and statistical power assessing the effect of interventions in the context of mixture distributions with detection limits. Statistics in Medicine, 2006, 25, 2647-2657.	1.6	9
147	Confidence Intervals for Biomarker-based Human Immunodeficiency Virus Incidence Estimates and Differences using Prevalent Data. American Journal of Epidemiology, 2006, 165, 94-100.	3.4	9
148	Illustration of a Measure to Combine Viral Suppression and Viral Rebound in Studies of HIV Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 241-244.	2.1	9
149	Marginal Structural Models for Risk or Prevalence Ratios for a Point Exposure Using a Disease Risk Score. American Journal of Epidemiology, 2019, 188, 960-966.	3.4	9
150	Prevalence and 1-year incidence of frailty among women with and without HIV in the Women's Interagency HIV Study. Aids, 2019, 33, 357-359.	2.2	9
151	Generalizing the per-protocol treatment effect: The case of ACTG A5095. Clinical Trials, 2019, 16, 52-62.	1.6	9
152	Remdesivir and COVID-19. Lancet, The, 2020, 396, 953.	13.7	9
153	Fusion designs and estimators for treatment effects. Statistics in Medicine, 2021, 40, 3124-3137.	1.6	9
154	Cancer risk in HIV patients with incomplete viral suppression after initiation of antiretroviral therapy. PLoS ONE, 2018, 13, e0197665.	2.5	8
155	Survival of infants with spina bifida and the role of maternal prepregnancy body mass index. Birth Defects Research, 2019, 111, 1205-1216.	1.5	8
156	Estimating a Set of Mortality Risk Functions with Multiple Contributing Causes of Death. Epidemiology, 2020, 31, 704-712.	2.7	8
157	Brief Report. Epidemiology, 2016, 27, 848-851.	2.7	7
158	At-Risk Alcohol Use Among HIV-Positive Patients and the Completion of Patient-Reported Outcomes. AIDS and Behavior, 2018, 22, 1313-1322.	2.7	7
159	Parametric assumptions equate to hidden observations: comparing the efficiency of nonparametric and parametric models for estimating time to AIDS or death in a cohort of HIV-positive women. BMC Medical Research Methodology, 2018, 18, 142.	3.1	7
160	Comparing neighborhood and state contexts for women living with and without HIV: understanding the Southern HIV epidemic. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 1360-1367.	1.2	7
161	The Effects of Hepatitis C Infection and Treatment on All-cause Mortality Among People Living With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2019, 68, 1152-1159.	5.8	7
162	Dynamic Visual Display of Treatment Response in HIV-Infected Adults. Clinical Infectious Diseases, 2015, 61, e1-e4.	5.8	6

#	ARTICLE	IF	CITATIONS
163	Health Insurance Type and Control of Hypertension Among US Women Living With and Without HIV Infection in the Women's Interagency HIV Study. American Journal of Hypertension, 2017, 30, 594-601.	2.0	6
164	Asbestos standards: Impact of currently uncounted chrysotile asbestos fibers on lifetime lung cancer risk. American Journal of Industrial Medicine, 2018, 61, 383-390.	2.1	6
165	Neighborhood Poverty and Control of HIV, Hypertension, and Diabetes in the Women's Interagency HIV Study. AIDS and Behavior, 2020, 24, 2033-2044.	2.7	6
166	Clinical Effectiveness of Integrase Strand Transfer Inhibitor–Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada. Clinical Infectious Diseases, 2020, 73, e1408-e1414.	5.8	6
167	Transportability From Randomized Trials to Clinical Care: On Initial HIV Treatment With Efavirenz and Suicidal Thoughts or Behaviors. American Journal of Epidemiology, 2021, 190, 2075-2084.	3.4	6
168	Illustration of 2 Fusion Designs and Estimators. American Journal of Epidemiology, 2023, 192, 467-474.	3.4	6
169	Applying Quantitative Bias Analysis to Epidemiologic Data: By Timothy L. Lash, Matthew P. Fox, and Aliza K. Fink. American Journal of Epidemiology, 2009, 170, 1316-1317.	3.4	5
170	Time at Risk and Intention-to-treat Analyses. Epidemiology, 2015, 26, 112-118.	2.7	5
171	Sensitivity Analyses for Misclassification of Cause of Death in the Parametric G-Formula. American Journal of Epidemiology, 2018, 187, 1808-1816.	3.4	5
172	Estimating Human Immunodeficiency Virus (HIV) Prevention Effects in Low-incidence Settings. Epidemiology, 2019, 30, 358-364.	2.7	5
173	Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy. Aids, 2022, 36, 277-286.	2.2	5
174	Generalizing Trial Evidence to Target Populations in Non-Nested Designs: Applications to AIDS Clinical Trials. Journal of the Royal Statistical Society Series C: Applied Statistics, 2022, 71, 669-697.	1.0	5
175	Sample Size Calculations for the Mean in a Two Component Nonstandard Mixture Distribution. Biometrical Journal, 2004, 46, 565-571.	1.0	4
176	Survival analysis for recurrent event data: an application to childhood infectious diseases by P. J. Kelly and L. L. Lim,Statistics in Medicine 2000;19:13–33. Statistics in Medicine, 2006, 25, 1431-1433.	1.6	4
177	Hormonal Contraception and HIV Risk. Epidemiology, 2011, 22, 877-878.	2.7	4
178	Editorial: The Evolving Practice of Epidemiology. American Journal of Epidemiology, 2014, 179, 1-3.	3.4	4
179	Using Animations of Risk Functions to Visualize Trends in US All-Cause and Cause-Specific Mortality, 1968–2016. American Journal of Public Health, 2019, 109, 451-453.	2.7	4
180	Flexibly Accounting for Exposure Misclassification With External Validation Data. American Journal of Epidemiology, 2020, 189, 850-860.	3.4	4

#	Article	IF	Citations
181	Racial, ethnic, and gender disparities in hospitalizations among persons with HIV in the United States and Canada, 2005â€"2015. Aids, 2021, 35, 1229-1239.	2.2	4
182	Maternal HIV Infection and Spontaneous Versus Provider-Initiated Preterm Birth in an Urban Zambian Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, 860-868.	2.1	4
183	Marginal structural cox models with case-cohort sampling. Statistica Sinica, 2016, 26, 509-526.	0.3	4
184	A Fundamental Equivalence between Randomized Experiments and Observational Studies. Epidemiologic Methods, 2016, 5, .	0.9	3
185	Effects of Health Insurance Interruption on Loss of Hypertension Control in Women With and Women Without HIV. Journal of Women's Health, 2017, 26, 1292-1301.	3.3	3
186	Chronic hepatitis C virus infection and subsequent HIV viral load among women with HIV initiating antiretroviral therapy. Aids, 2018, 32, 653-661.	2.2	3
187	The Authors Respond. Epidemiology, 2018, 29, e14-e15.	2.7	3
188	Assessing Exposure-Response Trends Using the Disease Risk Score. Epidemiology, 2020, 31, e15-e16.	2.7	3
189	Standardizing Discrete-Time Hazard Ratios With a Disease Risk Score. American Journal of Epidemiology, 2020, 189, 1197-1203.	3.4	3
190	Comparing Parametric, Nonparametric, and Semiparametric Estimators: The Weibull Trials. American Journal of Epidemiology, 2021, 190, 1643-1651.	3.4	3
191	Demographic Trends in US HIV Diagnoses, 2008â€"2017: Data Movies. American Journal of Public Health, 2021, 111, 529-532.	2.7	3
192	Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years. Journal of Infectious Diseases, 2021, 224, 657-666.	4.0	3
193	Nonparametric estimator of relative time with application to the Acyclovir Prevention Trial. Clinical Trials, 2009, 6, 320-328.	1.6	2
194	Comparing results from multiple imputation and dynamic marginal structural models for estimating when to start antiretroviral therapy. Statistics in Medicine, 2016, 35, 4335-4351.	1.6	2
195	Nondogmatism. Annals of Epidemiology, 2016, 26, 231-233.	1.9	2
196	Dogmatists Cannot Learn. Epidemiology, 2017, 28, e10-e11.	2.7	2
197	Inverse Probability Weights for the Analysis of Polytomous Outcomes. American Journal of Epidemiology, 2018, 187, 1125-1127.	3.4	2
198	Estimating multiple timeâ€fixed treatment effects using a semiâ€Bayes semiparametric marginal structural Cox proportional hazards regression model. Biometrical Journal, 2018, 60, 100-114.	1.0	2

#	Article	IF	Citations
199	Nonparametric estimation of the cumulative incidence function under outcome misclassification using external validation data. Statistics in Medicine, 2019, 38, 5512-5527.	1.6	2
200	Proximal HbA1C Level and First Hypoglycemia Hospitalization in Adults With Incident Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1989-1998.	3.6	2
201	Impact of Medicare Part D on mental health treatment and outcomes for dual eligible beneficiaries with HIV. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 505-512.	1.2	2
202	Two-stage g-computation. Epidemiology, 2020, 31, 695-703.	2.7	2
203	Decreased Susceptibility of Marginal Odds Ratios to Finite-sample Bias. Epidemiology, 2021, 32, 648-652.	2.7	2
204	HIV viral exposure and mortality in a multicenter ambulatory HIV adult cohort, United States, 1995â€"2016. Medicine (United States), 2021, 100, e26285.	1.0	2
205	Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors. PLoS ONE, 2020, 15, e0242405.	2.5	2
206	Risk of adverse birth outcomes in two cohorts of pregnant women with HIV in Zambia. Epidemiology, 2022, Publish Ahead of Print, .	2.7	2
207	On the use of covariate supersets for identification conditions. Epidemiology, 2022, Publish Ahead of Print, .	2.7	2
208	Ensemble estimation and variable selection with semiparametric regression models. Biometrika, 2020, 107, 433-448.	2.4	1
209	A new smoking cessation â€œcascadeâ€•among women with or at risk for HIV infection. Aids, 2021, Publish Ahead of Print, 107-116.	2.2	1
210	The Authors Respond. Epidemiology, 2017, 28, e62-e63.	2.7	0
211	A Statistical Appraisal of Biomarker Selection Methods Applicable to HIV/AIDS Research. Handbook of Statistics, 2012, , 99-128.	0.6	0
212	Fermatâ€™s Passage. Epidemiology, 2020, 31, e47-e47.	2.7	0
213	Title is missing!. , 2020, 15, e0242405.		0
214	Title is missing!. , 2020, 15, e0242405.		0
215	Title is missing!. , 2020, 15, e0242405.		0
216	Title is missing!. , 2020, 15, e0242405.		0